Frazier Life Sciences Management, L.P.
Q3 2022 13F-HR Holdings
Net value change ($000)
+239,062
(22.6%)
New positions
7
Sold out positions
5
Turnover %
14.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| HilleVax, Inc. | 65,277 | 64.3% |
| RYTM | 46,403 | NEW |
| PHAT | 43,968 | 89.4% |
| Allakos Inc. | 29,327 | NEW |
| VRNA | 21,457 | NEW |
| CHINOOK THERAPEUTICS, INC. | 20,984 | 33.4% |
| SNDX | 20,530 | 33.4% |
| ACAD | 14,026 | NEW |
| COGT | 12,057 | 63.8% |
| MIRM | 11,010 | 15.9% |
Top Reduces (Value $000, Stocks/ETFs)
| Sierra Oncology, Inc. | -47,876 | -100.0% |
| ARQT | -13,777 | -7.7% |
| VRDN | -11,342 | -100.0% |
| Gracell Biotechnologies Inc. | -7,808 | -45.6% |
| PASG | -7,126 | -60.3% |
| ALPINE IMMUNE SCIENCES, INC. | -3,912 | -15.4% |
| AUTL | -2,586 | -24.4% |
| PCVX | -1,756 | -4.5% |
| SLN | -1,745 | -16.7% |
| IVERIC bio, Inc. | -1,635 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|